#WuhanPneumonia #Covid19 #Vaccine
Peru suspends clinical trials of Chinese COVID-19 vaccine as tester develops neurological problems
Peru has temporarily suspended clinical trials of a COVID-19 vaccine made by Chinese drug giant #Sinopharm after detecting neurological problems in one of its test volunteers.
The National Institute of Health in Lima said on Dec 11, 2020 that it had decided to interrupt the trial after a volunteer had difficulty moving their arms, according to local media.
"Several days ago we signalled, as we are required, to the regulatory authorities that one of our participants (in trials) presented neurological symptoms which could correspond to a condition called Guillain-Barre syndrome," said chief researcher German Malaga in comments to the press.
Guillain-Barre syndrome is a rare and non-contagious disorder which affects the movement of the arms and legs. Peru declared a temporary health emergency in five regions in June last year following multiple cases.
In the 1970s a campaign to vaccinate Americans against a supposedly devastating strain of swine flu ground to a halt after about 450 of those vaccinated developed the syndrome, which can also cause paralysis.
Peru's clinical trials for the Sinopharm vaccine were due to conclude this week, after testing around 12,000 people.
Source: Channel News Asia #Dec12
https://www.channelnewsasia.com/news/world/peru-suspends-clinical-trials-china-sinopharm-covid-19-vaccine-13757116
#GuillainBarreSyndrome #Paralysis
Peru suspends clinical trials of Chinese COVID-19 vaccine as tester develops neurological problems
Peru has temporarily suspended clinical trials of a COVID-19 vaccine made by Chinese drug giant #Sinopharm after detecting neurological problems in one of its test volunteers.
The National Institute of Health in Lima said on Dec 11, 2020 that it had decided to interrupt the trial after a volunteer had difficulty moving their arms, according to local media.
"Several days ago we signalled, as we are required, to the regulatory authorities that one of our participants (in trials) presented neurological symptoms which could correspond to a condition called Guillain-Barre syndrome," said chief researcher German Malaga in comments to the press.
Guillain-Barre syndrome is a rare and non-contagious disorder which affects the movement of the arms and legs. Peru declared a temporary health emergency in five regions in June last year following multiple cases.
In the 1970s a campaign to vaccinate Americans against a supposedly devastating strain of swine flu ground to a halt after about 450 of those vaccinated developed the syndrome, which can also cause paralysis.
Peru's clinical trials for the Sinopharm vaccine were due to conclude this week, after testing around 12,000 people.
Source: Channel News Asia #Dec12
https://www.channelnewsasia.com/news/world/peru-suspends-clinical-trials-china-sinopharm-covid-19-vaccine-13757116
#GuillainBarreSyndrome #Paralysis
CNA
Peru suspends clinical trials of Chinese COVID-19 vaccine
Peru has temporarily suspended clinical trials of a Covid vaccine made by Chinese drug giant Sinopharm after detecting neurological problems in ...
UAE Claims 86% effectiveness of Sinopharm COVID Vaccine, Experts Question Failure to Account for Clinical Test Data
The UAE health authorities announced on Wednesday (Dec 9) that the Chinese Sinopharm COVID-19 vaccine has been tested and confirmed to be 86% effective, making it the first country in the world to certify the effectiveness of a Chinese-made vaccine. However, some academics, holding a wait-and-see attitude, believe that the UAE authorities have not provided key and detailed information, including data from the Phase 3 clinical trials.
The UAE is one of the ten countries where two of Sinopharm’ vaccines are undergoing clinical trials. UAE indicated that it had approved an interim analysis of the vaccine’s Phase 3 clinical trial data, which showed 100% effectiveness in preventing mild symptoms from turning into moderate to severe conditions. They also claimed an overall effective protection rate of 86%, adding that the vaccine poses no serious safety concerns.
The Sinopharm Group did not confirm the news or comment to the media for several hours after UAE’s announcement. The New York Times even reported that it was disconnected when it tried to reach the group on the phone. It was only at dusk on Thursday (Dec 10) that Sinopharm uploaded its vaccine registration statement for the UAE. Still, it did not provide further data on the Phase 3 tests, such as the number of people infected with the vaccine and the volunteers’ age. The group also did not make any “welcome” remarks.
#UAE #China #Sinopharm #COVID19 #Vaccines #Trials #TestData #NewYorkTimes
Source: Stand News #Dec11
https://bit.ly/3i0j9zj
The UAE health authorities announced on Wednesday (Dec 9) that the Chinese Sinopharm COVID-19 vaccine has been tested and confirmed to be 86% effective, making it the first country in the world to certify the effectiveness of a Chinese-made vaccine. However, some academics, holding a wait-and-see attitude, believe that the UAE authorities have not provided key and detailed information, including data from the Phase 3 clinical trials.
The UAE is one of the ten countries where two of Sinopharm’ vaccines are undergoing clinical trials. UAE indicated that it had approved an interim analysis of the vaccine’s Phase 3 clinical trial data, which showed 100% effectiveness in preventing mild symptoms from turning into moderate to severe conditions. They also claimed an overall effective protection rate of 86%, adding that the vaccine poses no serious safety concerns.
The Sinopharm Group did not confirm the news or comment to the media for several hours after UAE’s announcement. The New York Times even reported that it was disconnected when it tried to reach the group on the phone. It was only at dusk on Thursday (Dec 10) that Sinopharm uploaded its vaccine registration statement for the UAE. Still, it did not provide further data on the Phase 3 tests, such as the number of people infected with the vaccine and the volunteers’ age. The group also did not make any “welcome” remarks.
#UAE #China #Sinopharm #COVID19 #Vaccines #Trials #TestData #NewYorkTimes
Source: Stand News #Dec11
https://bit.ly/3i0j9zj
立場新聞 Stand News
阿聯酋宣稱中國國藥武肺疫苗 86% 有效 專家質疑未交代臨床測試數據 | 立場報道 | 立場新聞
阿聯酋衛生部門周三（9 日）宣布，指經測試證實中國國藥控股研發的武漢肺炎（COVID-19）疫苗有效率達 86...
#Covid19 #MadeinChina
Beijing Loyalist Criticises the Hong Kong Government for Lacking Proactiveness in Acquiring China-made Vaccines
Lo Chung-mau, Chief Executive of University of Hong Kong-Shenzhen Hospital, was vaccinated by China-owned Sinopharm in Shenzhen. Lo stated in an interview that instead of waiting for the 3rd phase clinical data for Sinovac’s vaccines, the Hong Kong government should seek the data from Sinpopharm or the National Medical Products Administration of China. Lo claimed that the Hong Kong government was passive and only “sitting and waiting”, instead of “striking out”.
In her response in the afternoon, Secretary for Food and Health Sophia Chan stated that all government bureaus were performing different tasks. On the one hand, the Hong Kong government has been contacting other countries and medicine manufacturers, to negotiate the logistics, clinical data and the acquisition of vaccines, in order to speed up the importation of vaccines to Hong Kong. On the other hand, through internal communication, the Hong Kong government has to keep in touch with medical teams and hospitals and discuss the arrangements of vaccinations for the public. once they were available in Hong Kong.
Moreover, Chan said the Scientific Committees under the Centre for Health and Protection in Hong Kong would be responsible for scheduling the vaccination and monitoring post- vaccination conditions.
The Advisory Panel on COVID-19 Vaccines would take up the task of approving any emergent use of vaccines. Chan stressed that the Hong Kong government was not “just sitting there and wait”.
Source: Stand News #Jan31
#WuhanPneumonia #SophiaChan #LoChungMau #BeijingLoyalist #Sinopharm #Sinovac #Covid19Vaccine
Beijing Loyalist Criticises the Hong Kong Government for Lacking Proactiveness in Acquiring China-made Vaccines
Lo Chung-mau, Chief Executive of University of Hong Kong-Shenzhen Hospital, was vaccinated by China-owned Sinopharm in Shenzhen. Lo stated in an interview that instead of waiting for the 3rd phase clinical data for Sinovac’s vaccines, the Hong Kong government should seek the data from Sinpopharm or the National Medical Products Administration of China. Lo claimed that the Hong Kong government was passive and only “sitting and waiting”, instead of “striking out”.
In her response in the afternoon, Secretary for Food and Health Sophia Chan stated that all government bureaus were performing different tasks. On the one hand, the Hong Kong government has been contacting other countries and medicine manufacturers, to negotiate the logistics, clinical data and the acquisition of vaccines, in order to speed up the importation of vaccines to Hong Kong. On the other hand, through internal communication, the Hong Kong government has to keep in touch with medical teams and hospitals and discuss the arrangements of vaccinations for the public. once they were available in Hong Kong.
Moreover, Chan said the Scientific Committees under the Centre for Health and Protection in Hong Kong would be responsible for scheduling the vaccination and monitoring post- vaccination conditions.
The Advisory Panel on COVID-19 Vaccines would take up the task of approving any emergent use of vaccines. Chan stressed that the Hong Kong government was not “just sitting there and wait”.
Source: Stand News #Jan31
#WuhanPneumonia #SophiaChan #LoChungMau #BeijingLoyalist #Sinopharm #Sinovac #Covid19Vaccine